KMX 12-DAY DEADLINE ALERT: CarMax (KMX) Sued Over Alleged "Temporary Demand Pull-Forward" and Loan Portfolio Risk - Hagens Berman
San Francisco, California--(Newsfile Corp. - December 21, 2025) - National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against CarMax, Inc. (NYSE: KMX) is January 2, 2026. The lawsuit alleges that CarMax and its executives provided materially false and misleading information by failing to disclose that the strong growth touted in Q1 2026 was merely a temporary,...
2025-12-21 3:24 PM EST
JHX INVESTOR DEADLINE: Hagens Berman Scrutinizing Claims in Pending Class Action Suit Challenging James Hardie's (JHX) Alleged Sales Practices
San Francisco, California--(Newsfile Corp. - December 18, 2025) - National shareholder rights law firm Hagens Berman is issuing a reminder to investors in James Hardie Industries plc (NYSE: JHX) as the December 23, 2025, lead plaintiff deadline approaches in a pending securities class action against James Hardie and certain of its key executives. The litigation alleges that James Hardie senior management misled investors by touting "robust" and "normal" inventory levels, while allegedly aware...
2025-12-18 10:30 AM EST
MLTX FINAL DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge
San Francisco, California--(Newsfile Corp. - December 14, 2025) - Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company's lead and sole drug candidate, sonelokimab...
2025-12-14 10:00 AM EST
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 27, 2025) - MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK). Global plaintiffs' rights firm Hagens Berman is actively investigating the alleged...
2025-11-27 2:16 PM EST
Synopsys (SNPS) Exists Amidst Securities Class Action, IP Unit Scrutiny-- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - Synopsys, Inc. (NASDAQ: SNPS), a leading electronic design automation (EDA) company, is facing a significant leadership shakeup and escalating legal pressure, highlighted by the recent departure of its Chief Revenue Officer (CRO). The company announced in a Form 8-K filing on November 4, 2025, that Rick Mahoney, who had served as CRO for three years, "will no longer serve as Synopsys' Chief Revenue Officer, effective...
2025-11-20 1:30 PM EST
James Hardie Industries (JHX) CFO Replaced, Lawsuit Alleging Securities Fraud Over Inventory Misstatements Pending -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - On November 17, 2025, James Hardie Industries plc (NYSE: JHX) announced the departure of its CFO (Rachel Wilson) who was immediately replaced by outsider Ryan Lada. This development follows the 34% August 20, 2025 collapse in James Hardie's share price and the class-action lawsuit filed against it and certain of its executives, alleging Defendants committed securities fraud by misleading investors about inventory levels and...
2025-11-20 1:29 PM EST
Inspire Medical Systems, Inc. (INSP) Faces Investor Suit Over Disastrous Inspire V Launch-- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - Inspire Medical Systems, Inc. (NYSE: INSP) is now grappling with a proposed class-action lawsuit alleging the company misled investors about the commercial readiness and demand for its critical "next generation" sleep apnea device, the Inspire V. The litigation zeroes in on the disparity between the company's confident assurances and the subsequent disastrous rollout that led to a dramatic stock crash. Prominent investor rights...
2025-11-20 1:28 PM EST
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claims. The firm urges investors in aTyr who suffered significant...
2025-11-20 1:27 PM EST
KMX SHAREHOLDER NOTICE: CarMax, Inc. (KMX) Class Period in Securities Class Action Expanded Amid CEO Termination -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - A new securities class action lawsuit against CarMax, Inc. (NYSE: KMX) has expanded the alleged class period to now include investors who purchased or otherwise acquired CarMax securities between June 20, 2025 and November 5, 2025. The period has been lengthened to include the severe market reaction to CarMax's announcement that it fired CEO Bill Nash, news which drove the price of CarMax shares down as much as $9.48 (-23%) on...
2025-11-20 1:22 PM EST
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 20, 2025) - Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively...
2025-11-20 1:12 PM EST
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 13, 2025) - A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS"). On this announcement, MoonLake investors saw the price of their shares...
2025-11-13 12:36 PM EST
KBR, Inc. (KBR) Cuts 2025 Revenue Due to TRANSCOM Termination, Securities Class Action Looms-Hagens Berman
San Francisco, California--(Newsfile Corp. - November 12, 2025) - A pending class-action lawsuit targeting KBR, Inc. (NYSE: KBR) alleges that the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract which negatively impacted the company's business prospects. The lawsuit seeks to represent investors who purchased or otherwise acquired KBR securities between May 6, 2025 and June 19, 2025. National shareholders rights...
2025-11-12 3:08 PM EST
KBR, Inc. (KBR) Cuts 2025 Revenue Due to TRANSCOM Termination, Securities Class Action Looms-Hagens Berman
San Francisco, California--(Newsfile Corp. - November 10, 2025) - A pending class-action lawsuit targeting KBR, Inc. (NYSE: KBR) alleges that the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract which negatively impacted the company's business prospects. The lawsuit seeks to represent investors who purchased or otherwise acquired KBR securities between May 6, 2025 and June 19, 2025. National shareholders rights...
2025-11-10 1:32 PM EST
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
San Francisco, California--(Newsfile Corp. - November 4, 2025) - A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The new class action, King v. aTyr Pharma Inc., filed in the U.S. District Court for the Southern District of California on behalf of investors who suffered substantial losses, now seeks to represent all persons and...
2025-11-04 6:37 PM EST
KBR, Inc. (KBR) Cuts 2025 Revenue Due to TRANSCOM Termination, Securities Class Action Looms-Hagens Berman
San Francisco, California--(Newsfile Corp. - November 4, 2025) - A pending class-action lawsuit targeting KBR, Inc. (NYSE: KBR) alleges that the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract which negatively impacted the company's business prospects. The lawsuit seeks to represent investors who purchased or otherwise acquired KBR securities between May 6, 2025 and June 19, 2025. National shareholders rights firm...
2025-11-04 6:27 PM EST
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman
San Francisco, California--(Newsfile Corp. - October 28, 2025) - A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS"). On this announcement, MoonLake investors saw the price of their shares...
2025-10-28 2:35 PM EDT
KBR, Inc. (KBR) Faces Securities Class Action Amid TRANSCOM Contract Termination - Hagens Berman
San Francisco, California--(Newsfile Corp. - October 28, 2025) - A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract. The suit, Norrman v. KBR, Inc., et al., No. 4:25-cv-04464 (S.D. Tex.), was filed after the company's stock plunged following the termination of a multi-billion-dollar deal. National shareholders rights firm Hagens Berman urges...
2025-10-28 2:31 PM EDT
LFMD FINAL DEADLINE ALERT: Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman
San Francisco, California--(Newsfile Corp. - October 26, 2025) - A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects. The suit, filed in in the Eastern District of New York, comes after a dramatic stock price decline in August following the company's earnings report. The firm urges investors in LifeMD...
2025-10-26 10:18 AM EDT
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
San Francisco, California--(Newsfile Corp. - October 23, 2025) - A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims. Blog: www.hbsslaw.com/blog The firm urges investors in aTyr who suffered significant...
2025-10-23 1:11 PM EDT
KBR, Inc. (KBR) Faces Securities Class Action Amid TRANSCOM Contract Termination-Hagens Berman
San Francisco, California--(Newsfile Corp. - October 16, 2025) - A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract. The suit, Norrman v. KBR, Inc., et al., No. 4:25-cv-04464 (S.D. Tex.), was filed after the company's stock plunged following the termination of a multi-billion-dollar deal. National shareholders rights firm Hagens Berman urges...
2025-10-16 4:55 PM EDT